JCR Plans 2026 Japanese Filing for Givinostat in Duchenne Muscular Dystrophy – JCR Pharmaceuticals
JCR Pharmaceuticals announced its development plan in Japan for givinostat, a treatment for Duchenne muscular dystrophy (DMD), following consultation with the Pharmaceuticals and Medical Devices Agency (PMDA).
Based on the outcome of the consultation, JCR plans to:
• Submit a marketing authorization application in Japan in 2026, primarily using overseas clinical data
• Obtain approval and launch the treatment in Japan in 2027
• Conduct a separate clinical trial in Japanese patients with DMD to evaluate pharmacokinetics and safety
Givinostat is an oral histone deacetylase inhibitor licensed from Italfarmaco S.p.A. It has already been approved in multiple countries and regions, including the United States, the European Union, and the United Kingdom, for the treatment of DMD in patients aged 6 years and older, in accordance with local prescribing information. As announced in December 2025, JCR holds exclusive rights to develop and commercialize the treatment in Japan. Because its mechanism of action is not dependent on specific dystrophin gene mutations, givinostat has the potential to be used in patients with DMD regardless of underlying mutation type.
“Following our consultation with PMDA, we have established a specific development plan in Japan. By using overseas clinical data, we believe this development strategy can help bring this treatment to patients with DMD in Japan more quickly. DMD remains an area of significant unmet medical need, and we will advance development with the goal of obtaining approval and launching it in Japan in 2027.” – Hiroyuki Sonoda, Ph.D., President and Chief Scientific Officer of JCR.
JCR remains committed to advancing research and development to help meet the expectations of patients and families waiting for effective treatment options.
The impact of this announcement on JCR’s consolidated financial results for this fiscal year (ending March 31, 2027) is expected to be minor.
